Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?
作者信息
Ramaswamy Vijay, Bartels Ute
机构信息
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
出版信息
Neuro Oncol. 2021 Oct 1;23(10):1627-1628. doi: 10.1093/neuonc/noab164.
Abstract
摘要
相似文献
1
Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?司美替尼治疗视路胶质瘤：拨开迷雾，（尚未）走出困境？
Neuro Oncol. 2021 Oct 1;23(10):1627-1628. doi: 10.1093/neuonc/noab164.
2
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.司美替尼治疗无神经纤维瘤病1型（NF1）的复发性视路和下丘脑低级别胶质瘤儿童的II期试验：一项儿童脑肿瘤协作组研究
Neuro Oncol. 2021 Oct 1;23(10):1777-1788. doi: 10.1093/neuonc/noab047.
3
Separation of outer retinal layers secondary to selumetinib.司美替尼继发的视网膜外层分离
J AAPOS. 2016 Jun;20(3):268-71. doi: 10.1016/j.jaapos.2016.01.012. Epub 2016 Apr 21.
4
An electron microscopic study of normal optic nerve and of an optic-nerve glioma.正常视神经及视神经胶质瘤的电子显微镜研究。
J Neurosurg. 1961 Jul;18:466-78. doi: 10.3171/jns.1961.18.4.0466.
5
Bilateral optic pathway glioma with intracranial calcification: magnetic resonance imaging and magnetic resonance spectroscopy findings.双侧视神经通路胶质瘤伴颅内钙化：磁共振成像和磁共振波谱分析结果
Australas Radiol. 2005 Dec;49(6):489-92. doi: 10.1111/j.1440-1673.2005.01442.x.
6
Targeting the mitogen‑activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in low‑grade glioma cells.靶向丝裂原活化蛋白激酶激酶和蛋白激酶 A 通路克服低级别神经胶质瘤细胞对 Selumetinib 的获得性耐药。
Oncol Rep. 2021 Feb;45(2):752-763. doi: 10.3892/or.2020.7867. Epub 2020 Nov 25.
7
Bilateral optic nerve glioma with misleading encephalogram.双侧视神经胶质瘤伴脑电图误导
Psychiatr Neurol (Basel). 1957 Sep-Oct;134(3-4):215-23. doi: 10.1159/000138735.
8
Role of visual evoked potentials and optical coherence tomography in the screening for optic pathway gliomas in patients with neurofibromatosis type I.I 型神经纤维瘤病患者视神经胶质瘤筛查中视觉诱发电位和光学相干断层扫描的作用。
Eur J Ophthalmol. 2021 Mar;31(2):698-703. doi: 10.1177/1120672120906989. Epub 2020 Feb 18.
9
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.西罗莫司在 BRAF 异常或神经纤维瘤病 1 型相关的复发性、难治性或进行性低度神经胶质瘤患儿中的应用：一项多中心、2 期试验。
Lancet Oncol. 2019 Jul;20(7):1011-1022. doi: 10.1016/S1470-2045(19)30277-3. Epub 2019 May 28.
10
[Diagnosis and therapy of optic nerve gliomas].[视神经胶质瘤的诊断与治疗]
Dia Med. 1952 Aug 6;24(49):1273.
引用本文的文献
1
Novel treatments in optic pathway gliomas.视路胶质瘤的新型治疗方法。
Front Ophthalmol (Lausanne). 2022 Sep 29;2:992673. doi: 10.3389/fopht.2022.992673. eCollection 2022.
2
The role of surgery for optic pathway gliomas in the era of precision medicine.精准医学时代视神经胶质瘤的手术作用。
Childs Nerv Syst. 2024 Oct;40(10):3075-3083. doi: 10.1007/s00381-024-06450-4. Epub 2024 May 14.
3
A Single-Center Treatment Experience of Gamma Knife Radiosurgery for Optic Pathway Glioma.伽玛刀放射外科治疗视神经胶质瘤的单中心治疗经验。
Biomed Res Int. 2022 Aug 9;2022:2043515. doi: 10.1155/2022/2043515. eCollection 2022.
4
Neurosurgery for Optic Pathway Glioma: Optimizing Multidisciplinary Management.视神经通路胶质瘤的神经外科手术：优化多学科管理
Front Surg. 2022 May 4;9:884250. doi: 10.3389/fsurg.2022.884250. eCollection 2022.
本文引用的文献
1
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.司美替尼治疗无神经纤维瘤病1型（NF1）的复发性视路和下丘脑低级别胶质瘤儿童的II期试验：一项儿童脑肿瘤协作组研究
Neuro Oncol. 2021 Oct 1;23(10):1777-1788. doi: 10.1093/neuonc/noab047.
2
Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas.对 1000 例小儿低级别胶质瘤的综合分子与临床分析。
Cancer Cell. 2020 Apr 13;37(4):569-583.e5. doi: 10.1016/j.ccell.2020.03.011.
3
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.一项评估曲美替尼治疗伴有 MAPK/ERK 通路激活的难治性肿瘤的儿童脑胶质瘤或丛状神经纤维瘤患者的 2 期研究：TRAM-01。
BMC Cancer. 2019 Dec 27;19(1):1250. doi: 10.1186/s12885-019-6442-2.
4
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.西罗莫司在 BRAF 异常或神经纤维瘤病 1 型相关的复发性、难治性或进行性低度神经胶质瘤患儿中的应用：一项多中心、2 期试验。
Lancet Oncol. 2019 Jul;20(7):1011-1022. doi: 10.1016/S1470-2045(19)30277-3. Epub 2019 May 28.
5
Pediatric low-grade gliomas: next biologically driven steps.小儿低度恶性神经胶质瘤：下一步生物学驱动的研究。
Neuro Oncol. 2018 Jan 22;20(2):160-173. doi: 10.1093/neuonc/nox141.
6
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.BRAF V600E在儿童低级别胶质瘤中的治疗及预后意义
J Clin Oncol. 2017 Sep 1;35(25):2934-2941. doi: 10.1200/JCO.2016.71.8726. Epub 2017 Jul 20.
7
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.一项 MEK 抑制剂 selumetinib（AZD6244）在复发性或难治性低级别脑胶质瘤患儿中的 I 期临床试验：一项儿科脑瘤协作组（PBTC）的研究。
Neuro Oncol. 2017 Aug 1;19(8):1135-1144. doi: 10.1093/neuonc/now282.
8
Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.Ⅱ期每周长春新碱化疗方案治疗初治进展性低级别脑胶质瘤患儿：加拿大儿科脑肿瘤联盟研究。
J Clin Oncol. 2016 Oct 10;34(29):3537-3543. doi: 10.1200/JCO.2016.68.1585.
9
Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study.决定儿童低级别胶质瘤成年幸存者长期预后的临床和治疗因素：一项基于人群的研究。
Cancer. 2016 Apr 15;122(8):1261-9. doi: 10.1002/cncr.29907. Epub 2016 Mar 10.
10
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.贝伐珠单抗联合伊立替康治疗复发性低级别胶质瘤患儿的疗效——儿科脑肿瘤联盟研究。
Neuro Oncol. 2014 Jan;16(2):310-7. doi: 10.1093/neuonc/not154. Epub 2013 Dec 4.
Zotero 插件